Rodrigo Machado-Vieira

Summary

Country: Brazil

Publications

  1. pmc A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania
    Rodrigo Machado-Vieira
    Bipolar Disorder Research Program, Espirita Hospital of Porto Alegre, Porto Alegre, RS, Brazil
    J Clin Psychiatry 69:1237-45. 2008
  2. ncbi [Treatment-resistant mood disorders]
    Rodrigo Machado-Vieira
    Programa de Transtornos do Humor e Ansiedade, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892 3711, USA
    Rev Bras Psiquiatr 29:S48-54. 2007
  3. ncbi Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects
    Rodrigo Machado-Vieira
    Mood Disorders Program, HMIPV, Fundacao Faculdade Federal Ciencias Medicas de Porto Alegre and Bipolar Disorder Research Program, Espirita Hospital of Porto Alegre, Porto Alegre, Brazil
    Neurosci Lett 421:33-6. 2007
  4. pmc A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression
    Nancy Diazgranados
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Arch Gen Psychiatry 67:793-802. 2010
  5. pmc The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior
    Jing Du
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20878, USA
    J Neurosci 28:68-79. 2008
  6. pmc Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist
    Rodrigo Machado-Vieira
    Mood and Anxiety Disorders Program, Laboratory of Molecular Psychiatry and Experimental Therapeutics, National Institute of Mental Health NIMH, National Institutes of Health NIH, Department of Health and Human Services, Bethesda, Maryland, USA
    J Clin Psychiatry 70:1662-6. 2009
  7. pmc A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors
    Jing Du
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:11573-8. 2010
  8. pmc Early improvement with lithium in classic mania and its association with later response
    Rodrigo Machado-Vieira
    Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, NIH, Bethesda, MD, USA
    J Affect Disord 144:160-4. 2013
  9. pmc Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder
    Nancy Diazgranados
    National Institute of Mental Health, and Department of Human Health Services, Bethesda, Maryland, USA
    J Clin Psychiatry 71:1605-11. 2010
  10. pmc An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression
    Giacomo Salvadore
    Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    Int J Neuropsychopharmacol 15:1063-72. 2012

Detail Information

Publications38

  1. pmc A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania
    Rodrigo Machado-Vieira
    Bipolar Disorder Research Program, Espirita Hospital of Porto Alegre, Porto Alegre, RS, Brazil
    J Clin Psychiatry 69:1237-45. 2008
    ..This study aimed to evaluate the efficacy and tolerability of the purinergic agents allopurinol and dipyridamole combined with lithium in bipolar mania...
  2. ncbi [Treatment-resistant mood disorders]
    Rodrigo Machado-Vieira
    Programa de Transtornos do Humor e Ansiedade, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892 3711, USA
    Rev Bras Psiquiatr 29:S48-54. 2007
    ..The objective of this literature review is to evaluate the current concepts of treatment resistance and refractoriness in mood disorders...
  3. ncbi Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects
    Rodrigo Machado-Vieira
    Mood Disorders Program, HMIPV, Fundacao Faculdade Federal Ciencias Medicas de Porto Alegre and Bipolar Disorder Research Program, Espirita Hospital of Porto Alegre, Porto Alegre, Brazil
    Neurosci Lett 421:33-6. 2007
    ..Antioxidant effects using lithium in mania were shown, and further studies are necessary to evaluate the potential role of these effects in the pathophysiology and therapeutics of BD...
  4. pmc A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression
    Nancy Diazgranados
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Arch Gen Psychiatry 67:793-802. 2010
    ..Pharmacological strategies that produce rapid antidepressant effects-for instance, within a few hours or days-would have an enormous impact on patient care and public health...
  5. pmc The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior
    Jing Du
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20878, USA
    J Neurosci 28:68-79. 2008
    ..These studies provide novel insights into the role of hippocampal GluR1/2 receptors in mediating facets of the manic syndrome and offer avenues for the development of novel therapeutics for these disorders...
  6. pmc Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist
    Rodrigo Machado-Vieira
    Mood and Anxiety Disorders Program, Laboratory of Molecular Psychiatry and Experimental Therapeutics, National Institute of Mental Health NIMH, National Institutes of Health NIH, Department of Health and Human Services, Bethesda, Maryland, USA
    J Clin Psychiatry 70:1662-6. 2009
    ..This study investigated whether changes in brain-derived neurotrophic factor (BDNF) levels are associated with the initial antidepressant effects of ketamine, a high-affinity N-methyl-D-aspartate (NMDA) antagonist...
  7. pmc A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors
    Jing Du
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:11573-8. 2010
    ..The kinesin cargo system may provide valuable novel targets for the development of new therapeutics for mood disorders...
  8. pmc Early improvement with lithium in classic mania and its association with later response
    Rodrigo Machado-Vieira
    Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, NIH, Bethesda, MD, USA
    J Affect Disord 144:160-4. 2013
    ..This study investigated whether early improvement (within one week) to lithium monotherapy predicted later response and remission in individuals with BD mania...
  9. pmc Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder
    Nancy Diazgranados
    National Institute of Mental Health, and Department of Human Health Services, Bethesda, Maryland, USA
    J Clin Psychiatry 71:1605-11. 2010
    ..We examined the effects of a single dose of ketamine on suicidal ideation in subjects with treatment-resistant major depressive disorder (MDD)...
  10. pmc An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression
    Giacomo Salvadore
    Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    Int J Neuropsychopharmacol 15:1063-72. 2012
    ....
  11. pmc Effects of lithium on oxidative stress parameters in healthy subjects
    Rushaniya Khairova
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Mol Med Rep 5:680-2. 2012
    ..Overall, the present findings indicate a potential role for the antioxidant effects of lithium in healthy subjects, supporting its neuroprotective profile in bipolar disorder (BD) and, possibly, in neurodegenerative processes...
  12. pmc Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode
    Giacomo Salvadore
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, CRC Unit 7 Southeast, Room 7 3445, Bethesda, Maryland, 20892 1285, USA
    Prog Neuropsychopharmacol Biol Psychiatry 34:819-21. 2010
    ..Overall, our findings suggest a novel mechanism in the pathophysiology of BPD...
  13. pmc The neurobiology of the switch process in bipolar disorder: a review
    Giacomo Salvadore
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland, USA
    J Clin Psychiatry 71:1488-501. 2010
    ..In this review, we summarize the clinical evidence regarding somatic interventions associated with switching, with a particular focus on the biologic underpinnings presumably involved in the switch process...
  14. pmc Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder
    Rodrigo Machado-Vieira
    Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Health and Human Services, Bethesda, MD 20892 1282, USA
    J Clin Psychiatry 69:946-58. 2008
    ..This article reviews the published data related to different aspects of rapid improvement of depressive symptoms...
  15. pmc New therapeutic targets for mood disorders
    Rodrigo Machado-Vieira
    Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    ScientificWorldJournal 10:713-26. 2010
    ....
  16. pmc Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression
    Lobna Ibrahim
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, CRC Unit 7 Southeast, Room 7 3445, Bethesda, MD 20892, USA
    Prog Neuropsychopharmacol Biol Psychiatry 35:1155-9. 2011
    ..However, it remains unknown whether ketamine is equally effective in patients with MDD who previously also did not respond to electroconvulsive therapy (ECT)...
  17. pmc Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): a pilot study
    Lobna Ibrahim
    Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, United States
    Brain Res Bull 86:129-33. 2011
    ..These results suggest that SD is associated with mood-related changes in plasma VEGF levels, but not plasma BDNF levels. Further studies using larger sample sizes are needed to confirm these preliminary findings...
  18. pmc Glutamatergic modulators: the future of treating mood disorders?
    Carlos Zarate
    Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Harv Rev Psychiatry 18:293-303. 2010
    ..Overall, this system holds considerable promise for developing the next generation of novel therapeutics for the treatment of bipolar disorder and major depressive disorder...
  19. pmc Dynamic regulation of mitochondrial function by glucocorticoids
    Jing Du
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 106:3543-8. 2009
    ....
  20. pmc The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders
    Rodrigo Machado-Vieira
    Experimental Therapeutics, Mood and Anxiety Disorders Research Program, NIMH NIH, Bethesda, Maryland 20892, USA
    Neuroscientist 15:525-39. 2009
    ..In therapeutically relevant paradigms, ketamine preferentially targets postsynaptic AMPA/NMDA receptors, and riluzole preferentially targets presynaptic voltage-operated channels and glia...
  21. pmc Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders
    Rodrigo Machado-Vieira
    Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Curr Pharm Des 15:1595-611. 2009
    ..This paper reviews the currently available knowledge regarding the role of the glutamatergic system in the etiopathogenesis of mood disorders and putative glutamate modulators...
  22. pmc Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine
    Giacomo Salvadore
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Neuropsychopharmacology 35:1415-22. 2010
    ..73, p=0.0021, FDR <0.05).These data implicate the pgACC and its putative interaction with the amygdala in predicting antidepressant response to ketamine in a working memory task context...
  23. pmc Bax inhibitor 1, a modulator of calcium homeostasis, confers affective resilience
    Joshua G Hunsberger
    National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    Brain Res 1403:19-27. 2011
    ..Together, these data suggest that BI-1, through its actions on calcium homeostasis, may confer affective resiliency in multiple animal models of depression and anhedonia...
  24. pmc Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions
    Rodrigo Machado-Vieira
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, and Department of Health and Human Services, Bethesda, MD 20892, USA
    CNS Neurosci Ther 17:699-704. 2011
    ....
  25. pmc A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder
    Rushaniya A Khairova
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Neuropsychopharmacol 12:561-78. 2009
    ....
  26. pmc Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania
    Steven T Szabo
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Building 35, 1C912, Bethesda, MD 20892, USA
    Neuropharmacology 56:47-55. 2009
    ..These results suggest that PKC modulators or their intracellular targets may ultimately represent novel avenues for the development of new therapeutics for mood disorders...
  27. pmc The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder
    Rodrigo Machado-Vieira
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland, USA
    Biol Psychiatry 69:344-52. 2011
    ..Here, we examined the effects of the Bcl-2 gene single nucleotide polymorphism (SNP) rs956572 on intracellular Ca(2+) dynamics in patients with BPD...
  28. pmc Ketamine and the next generation of antidepressants with a rapid onset of action
    Rodrigo Machado-Vieira
    Experimental Therapeutics Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Pharmacol Ther 123:143-50. 2009
    ..Overall, understanding the molecular basis of this work will likely lead to the ultimate development of improved therapeutics for MDD...
  29. ncbi Increased cerebrospinal fluid levels of S100B protein in rat model of mania induced by ouabain
    Rodrigo Machado-Vieira
    Mood Disorders Program, HMIPV, Fundacao Faculdade Federal de Ciencias Medicas de Porto Alegre, RS, Brasil
    Life Sci 76:805-11. 2004
    ..Our findings reinforce the role of astroglial cells in the pathogenesis of bipolar disorder and S100B protein as a marker of bipolar mania...
  30. pmc Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder?
    Paul J Fitzgerald
    Section on Behavioral Science and Genetics, Laboratory for Integrative Neuroscience, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD 20852 9411, USA
    Neurobiol Dis 40:608-21. 2010
    ..Collectively, these findings demonstrate mania-related abnormalities in GluA1 KO and, combined with previous findings, suggest this mutant may provide a novel model of features of schizoaffective disorder...
  31. ncbi Perspectives for the development of animal models of bipolar disorder
    Rodrigo Machado-Vieira
    Laboratory of Experimental Psychiatry, Hospital de Clinicas de Porto Alegre, School of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil
    Prog Neuropsychopharmacol Biol Psychiatry 28:209-24. 2004
    ..In this review, we propose that new genetics approaches involving potential animal models of BD are a promising new area for further development...
  32. pmc The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis
    Rodrigo Machado-Vieira
    Experimental Therapeutics, Mood and Anxiety Disorders Research Program, NIMH NIH, Department of Health and Human Services, Bethesda, MD 20892, USA
    Bipolar Disord 11:92-109. 2009
    ..Continued work to decipher lithium's molecular actions will likely lead to the development of not only improved therapeutics for BD, but to neurotrophic enhancers that could prove useful in the treatment of many other illnesses...
  33. ncbi Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode
    Rodrigo Machado-Vieira
    Mood Disorders Program, Fundação Faculdade Federal Ciências Medicas de Porto Alegre, Bipolar Disorder Research Program, Espirita Hospital of Porto Alegre, Porto Alegre, Brazil
    Biol Psychiatry 61:142-4. 2007
    ..Also, previous studies demonstrated a role for BDNF in the pathophysiology and clinical presentation of mood disorders...
  34. ncbi A proton magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in acute mania
    Benicio N Frey
    Laboratorio de Psiquiatría Experimental, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brasil
    Hum Psychopharmacol 20:133-9. 2005
    ..N-acetyl-L-aspartate (NAA), choline-containing molecules (Cho), creatine plus phosphocreatine (Cr) and myoinositol (Ino) were measured...
  35. ncbi [Neuropatological and neurochemical abnormalities in bipolar disorder]
    Benicio Noronha Frey
    Laboratorio de Psiquiatría Experimental, Hospital de Clinicas de Porto Alegre, Brazil
    Rev Bras Psiquiatr 26:180-8. 2004
    ..The objective of this paper is to review the findings in neuropathology and cellular biochemistry...
  36. ncbi Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: Developing treatments using an integrated translational approach
    Rodrigo Machado-Vieira
    Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, NIH, Bethesda, MD, USA
    World J Biol Psychiatry 15:84-95. 2014
    ..These studies will likely focus on more precise diagnoses and a personalized medicine paradigm in order to develop better treatments for those who need them most. ..
  37. pmc Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants
    Mark J Niciu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, Maryland
    Depress Anxiety 31:297-307. 2014
    ..In sum, the combination of target engagement and well-qualified disease-related measures are crucial to improve our pathophysiological understanding, personalize treatment selection, and expand our armamentarium of novel therapeutics. ..
  38. ncbi [The multidisciplinary team approach to the treatment of bipolar disorder: an overview]
    Rodrigo Machado-Vieira
    Mood Disorders Program, Fundacao Faculdade Federal de Ciencias Medicas de Porto Alegre, Hospital Materno Infantil Presidente Vargas, Porto Alegre, RS
    Rev Bras Psiquiatr 26:51-3. 2004
    ..The objective of this approach is early identification of prodromal symptoms in order to prevent hospitalization and behavioral dysfunction...